Article Information
History
- June 16, 2022.
Article Versions
- You are currently viewing Version 1 of this article (June 16, 2022 - 09:30).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Scott Dryden-Peterson, MD, MSc1,2,3,*,
- Andy Kim, BS1,4,
- Arthur Y. Kim, MD1,4,
- Ellen C. Caniglia, ScD5,
- Inga Lennes, MD, MPH, MBA4,
- Rajesh Patel, MD, MPH7,
- Lindsay Gainer, RN6,
- Lisa Dutton, RN1,
- Elizabeth Donahue, RN, MSN, NP-C1,
- Rajesh T. Gandhi, MD4,
- Lindsey R. Baden, MD1 and
- Ann E. Woolley, MD, MPH1
- 1Brigham and Women’s Hospital, Boston, Massachusetts
- 2Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health
- 3Botswana Harvard AIDS Institute
- 4Massachusetts General Hospital, Boston, Massachusetts
- 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- 6Mass General Brigham Integrated Care
- 7Beth Israel Lahey Health, Cambridge, Massachusetts
- ↵*Corresponding Author:
Scott Dryden-Peterson, MD, MSc, Division of Infectious Diseases, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. Work: (617) 732-8881. sldrydenpeterson{at}bwh.harvard.edu
Posted June 16, 2022.
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
